Lenvatinib for Hepatocellular Carcinoma: A Literature Review

Lenvatinib, which is an oral multikinase inhibitor, showed non-inferiority to the sorafenib in terms of overall survival (OS) and a higher objective response rate (ORR) and better progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC). A good liver function and Barcelona Cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatanaka, Takeshi, Naganuma, Atsushi, Kakizaki, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825021/
https://www.ncbi.nlm.nih.gov/pubmed/33418941
http://dx.doi.org/10.3390/ph14010036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825021/
https://www.ncbi.nlm.nih.gov/pubmed/33418941
http://dx.doi.org/10.3390/ph14010036

Ejemplares similares